Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Recurrent Melanoma: early-phase trial registry
1 of 25 indexed Recurrent Melanoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #652 of 28,707 conditions by registered trial count.
25 US clinical trials · 1 currently recruiting · #652 of 28,707 conditions by registered trial count
Recurrent Melanoma: 25 US clinical trials tracked, 1 recruiting.
Recurrent Melanoma is the subject of 25 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 22 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 20 of these trials.
Enrollment posture brief
Registry condition recurrent-melanoma
OPEN 1 | RECR 4% | LATE 3 | EARLY 22 | RANK #652 | SPON 20
Volume-matched condition peers
Nearest open-share peer: Stage IIIB Breast Cancer (4% recruiting · 24 trials)
Recurrent Melanoma lists 1 open slots (4% of 25 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Recurrent Melanoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Recurrent Melanoma is recruiting below its size-band peers.
1 of 25 indexed trials (4%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Recurrent Melanoma research.
National Cancer Institute (NCI) accounts for 20 of 25 trials (80%). 5 distinct sponsors appear on at least one study for this condition label.
-
Most Recurrent Melanoma trials plan to enrol fewer than 100 people.
Median target enrolment is 50 among the 24 trials that report a genuine target (sentinel values excluded). 19 of those (79.2%) plan for fewer than 100 participants.
-
Recurrent Melanoma research is mostly interventional.
25 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
25 total, page 1 of 1
Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel)
M.D. Anderson Cancer Center
NCT06660420
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
National Cancer Institute (NCI)
NCT01274338
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
National Cancer Institute (NCI)
NCT02224781
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT01134614
Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT01708941
Dinaciclib in Treating Patients With Stage IV Melanoma
National Cancer Institute (NCI)
NCT00937937
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
National Cancer Institute (NCI)
NCT02298959
Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
National Cancer Institute (NCI)
NCT02965716
Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma
National Cancer Institute (NCI)
NCT01303341
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT00110019
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
National Cancer Institute (NCI)
NCT02304458
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
Mayo Clinic
NCT00655655
Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma
National Cancer Institute (NCI)
NCT00349206
Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma
National Cancer Institute (NCI)
NCT00072163
Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma
National Cancer Institute (NCI)
NCT00005949
Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers
National Cancer Institute (NCI)
NCT00074308
Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma
National Cancer Institute (NCI)
NCT00003895
Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma
Abramson Cancer Center at Penn Medicine
NCT01103635
Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
Mayo Clinic
NCT01328535
Decitabine in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
NCT00030615
Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors
National Cancer Institute (NCI)
NCT00112476
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
Alliance for Clinical Trials in Oncology
NCT00060333
Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma
National Cancer Institute (NCI)
NCT00397982
Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma
National Cancer Institute (NCI)
NCT01196416
flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer
National Cancer Institute (NCI)
NCT00019396
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 11 |
| Phase 2 | 11 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Recurrent Melanoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Recurrent Melanoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Recurrent Melanoma page
25 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Recurrent Melanoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Recurrent Melanoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Melanoma condition card totals 25 registered trials; most-linked intervention laboratory biomarker analysis; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.